86exporter.com Home       Products Catalog      Suppliers Catalog      Log In        Sign up
      About Us
      Profile
      Products
      Contact Us


Shenzhen Nexconn Pharmatechs Ltd

Products >> Rivaroxaban

Rivaroxaban

Build Your Online Product Catalogs?



Description
Product Name: Rivaroxaban
Supply Ability:
Related proudcts
Specifications 99%+ purity, unknown single impurity<0.1%
Price Term: according to the customers' request
Port of loading: according to the customers' request
Minimum Order
Unit Price:

Rivaroxaban was first approved by Health Canada on September 15, 2008, then approved by European Medicine Agency£¨EMA£©on September 30, 2008, and approved by the US Food and Drug Administration£¨FDA£© on July 01,2011. It was developed by Bayer and Janssen, then marketed as Xarelto by Bayer Pharma. In CA and EU and by Janssen in the US.
Rivaroxaban is a selective inhibitor of FXa. It inhibits both free Factor Xa and Factor Xa bound in the prothrombinase complex. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation. Xarelto co-administered with acetylsalicylic acid(ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome(ACS) with elevated cardiac biomarkers.

Contact Us
Company: Shenzhen Nexconn Pharmatechs Ltd
Contact: Mr. Jason Scorpion
Address: Rm.1249-1251, Jiaxiye Plaza, No.318 Minzhi Ave., Longhua New Dist
Postcode: 518131
Tel: +86-755-89396905
Fax: +86-755-22712255
E-mail:         


Copyright© Shenzhen Nexconn Pharmatechs Ltd All Rights Reserved.
Tel : +86-755-89396905 Fax : +86-755-22712255
Powered by 86exporter.com